Lung Cancer Treatment in Hyderabad
Reviewed May 2026 · Dr. Madhav Danthala
Lung cancer is no longer a smoker's disease. In India, especially in women under 50, more than half of newly diagnosed lung cancers are in people who never smoked. Dr. Madhav Danthala provides treatment planning, chemotherapy, targeted therapy, and immunotherapy at KIMS-Sunshine Hospitals, Begumpet, and Peoples Polyclinic, Manikonda.
When to See a Doctor
Most persistent coughs are not cancer. The pattern that matters is when symptoms are new, persistent, and not explained by infection. Four signs warrant evaluation.
Dr. Danthala's Approach
Lung cancer care today depends as much on molecular testing as on imaging. Three principles shape every consultation.
-
Mutation-led planning
Every adenocarcinoma is profiled for EGFR, ALK, ROS1, KRAS, BRAF, and other actionable mutations before chemotherapy is started, where feasible.
-
More than one path
For locally advanced disease, surgery-first, neoadjuvant chemoradiation, and immunotherapy combinations are all medically defensible. The path is chosen with the patient.
-
Clear, structured communication
Every consult ends with a written summary of options, expected timelines, and the trade-offs each plan carries — so decisions are made calmly, not under pressure.
Treatment Options
Modern lung cancer care is built on a molecular profile, not just a stage. Every adenocarcinoma is tested for actionable mutations before chemotherapy is started where feasible. Below are the major treatment modalities, ordered by how they typically appear in a treatment plan.
Lobectomy or sublobar resection for early-stage NSCLC
For stage I-II non-small-cell lung cancer, surgical resection (typically lobectomy with mediastinal lymph node sampling) offers the best chance of cure. Sublobar resection (segmentectomy or wedge) is acceptable for small peripheral tumours under 2 cm. Video-assisted thoracoscopic surgery (VATS) and robotic approaches reduce recovery time. Adjuvant therapy may follow based on stage and molecular profile.
Osimertinib, alectinib, sotorasib — oral and effective
EGFR mutations (osimertinib), ALK rearrangements (alectinib, brigatinib), ROS1 (entrectinib), KRAS G12C (sotorasib, adagrasib), BRAF V600E, RET, MET, NTRK, and HER2 each have approved oral targeted therapies. These often outperform chemotherapy as first-line therapy and are increasingly being used in the adjuvant setting (osimertinib post-surgery for EGFR+ stage IB-IIIA disease).
PD-1/PD-L1 inhibitors — alone or with chemotherapy
Pembrolizumab, atezolizumab, durvalumab, and nivolumab are now standard for advanced NSCLC without targetable mutations. PD-L1 expression guides whether immunotherapy is given alone or combined with chemotherapy. Durvalumab consolidation after chemoradiation is standard for unresectable stage III disease (PACIFIC regimen). Adjuvant immunotherapy is also increasingly used post-resection.
Platinum doublets, SBRT, concurrent chemoradiation
Platinum-based chemotherapy (cisplatin/carboplatin with pemetrexed or paclitaxel) remains an option in advanced disease without targetable drivers. Stereotactic body radiation therapy (SBRT) is curative-intent for inoperable early-stage NSCLC. Concurrent chemoradiation is the standard for unresectable stage III disease, followed by durvalumab consolidation. Small-cell lung cancer is treated primarily with platinum + etoposide combined with atezolizumab or durvalumab.
Treatment is shaped by stage, molecular profile, performance status, and patient preference. The list above is the menu. The right plan is built with the patient in the room.
Frequently Asked Questions
Can lung cancer happen to people who never smoked?
Yes. In India, especially in women under 50, more than half of newly diagnosed lung cancers are in non-smokers. Causes include air pollution, indoor cooking smoke, occupational exposure, secondhand smoke, and genetic mutations like EGFR which are more common in Asian populations. Tobacco — when it is the driver — also causes oral and laryngeal cancers; the risk profile overlaps and screening conversations should cover both.
When should a persistent cough be evaluated?
Any cough lasting more than three weeks, regardless of smoking history. Immediate concern if there is blood in the sputum, weight loss, breathlessness, or persistent chest pain.
What is EGFR mutation in lung cancer?
EGFR is a gene that, when mutated, drives some lung cancers. EGFR mutations are found in 30 to 40 percent of Asian non-smoker adenocarcinomas. These cancers respond well to targeted oral therapies like osimertinib.
Is low-dose CT screening recommended in India?
For heavy smokers aged 50 to 80 with significant pack-year history, yes. In non-smokers, evidence-based guidelines are still emerging. Discuss imaging with your doctor on an individual basis.
What treatments are available?
Surgery for early-stage NSCLC, chemotherapy, targeted therapy (for EGFR, ALK, ROS1, KRAS G12C, etc.), immunotherapy for PD-L1 positive cases, and radiation. Dr. Danthala coordinates care across surgical, medical, and radiation oncology.
About Dr. Madhav Danthala
Dr. Madhav Danthala is a medical oncologist and hemato-oncologist practising at KIMS-Sunshine Hospitals, Begumpet and Peoples Polyclinic, Manikonda, Hyderabad. His clinical interests span breast, lung, gastrointestinal, gynaecologic, and head & neck cancers, with a focus on subtype-led treatment planning, second opinions, and shared decision-making. He has trained at premier oncology institutes and performed 300+ stem cell transplants.
Trusted guidelines & further reading
- ESMO — Cancer Guides for Patients European Society for Medical Oncology patient guides — freely accessible, evidence-based.
- ASCO / Cancer.Net — Lung Cancer American Society of Clinical Oncology patient education portal.
- NCI / Cancer.gov — Lung Cancer US National Cancer Institute clinical treatment summaries.
From our blog
- Lung Cancer in Non-Smokers: India's Quiet Epidemic Why non-smokers — especially Indian women under 50 — are now the most often delayed-to-diagnosis lung cancer patients.
- The Two-Oncologist Rule: When to Get a Second Opinion Lung cancer with a targetable mutation often has multiple defensible treatment paths — second opinions help navigate them.